Q-omics provides the consensus-scored MED7 profile across patient tissues and cancer cell-line models. MED7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MED7 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, MED7 protein abundance shows 20,474 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where MED7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED7 survival associations across molecular data types. MED7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED7 RNA expression–survival associations across cancer types. High MED7 expression shows unfavorable associations in HNSC, LIHC, SCLC and UVM, but favorable associations in KIRC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MED7 RNA expression.
This table summarizes MED7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MED7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED7 shows lower tumor expression in THCA, KICH, LUSC, COAD and LUAD and higher tumor expression in LIHC. The THCA box plot shows higher MED7 RNA expression in normal versus tumor tissue (log2 FC = −0.558, t-test p < 0.001).
This table shows molecular features associated with MED7 in patient tissues and cancer cell lines. In patient samples, MED7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SKIN.
